Clinical Report: The Role of lncRNA PVT1 in the Pathogenesis of Oral Squamous Cell Carcinoma

Overview

LncRNA PVT1 is significantly overexpressed in oral squamous cell carcinoma (OSCC) and plays a crucial role in its pathogenesis by regulating tumor cell proliferation, invasion, and chemoresistance. This review highlights the potential of lncRNA PVT1 as a diagnostic biomarker and therapeutic target in OSCC.

Background

Oral squamous cell carcinoma (OSCC) is a prevalent malignancy with high recurrence and metastasis rates, leading to poor survival outcomes. Despite advancements in treatment, the five-year survival rate remains low, underscoring the need for effective biomarkers and therapeutic targets. LncRNA PVT1 has emerged as a significant player in OSCC, influencing critical oncogenic processes.

Data Highlights

No numerical data available in the source material.

Key Findings

• LncRNA PVT1 is frequently overexpressed in OSCC and correlates with advanced TNM stage and poor survival.
• PVT1 acts as a competitive endogenous RNA, sequestering tumor-suppressive microRNAs and promoting tumor cell proliferation.
• The PVT1/miR-7-5p/CDKL1 axis enhances OSCC cell proliferation by accelerating the G1/S transition.
• PVT1 upregulates SERPINB4 through the PVT1/miR-185-5p/SERPINB4 axis, driving proliferation, migration, and invasion in OSCC cells.
• lncRNA PVT1 is involved in the induction of epithelial-mesenchymal transition (EMT) and modulation of key signaling pathways.
• Potential for lncRNA PVT1 to serve as a novel diagnostic biomarker and therapeutic target in OSCC.

Clinical Implications

The findings suggest that lncRNA PVT1 could be a valuable biomarker for predicting OSCC progression and patient outcomes. Targeting lncRNA PVT1 may offer new therapeutic strategies to combat OSCC, particularly in overcoming chemoresistance.

Conclusion

LncRNA PVT1 plays a pivotal role in the pathogenesis of OSCC, influencing key oncogenic processes. Its potential as a biomarker and therapeutic target warrants further investigation to improve clinical outcomes in OSCC patients.

References

1. Clinical Rheumatology, 2025 -- The Role of LncRNA PVT1 in Modulating CD4 + T Cell Imbalance in Systemic Lupus Erythematosus: Findings from Human Studies and MRL/lpr Mouse Models
2. Archives of Toxicology, 2021 -- Influence of microRNAs on the response to cadmium chloride in pancreatic ductal adenocarcinoma
3. The ASCO Post, 2016 -- Characteristics of HPV-Driven Nonoropharyngeal Squamous Cell Carcinomas of the Head and Neck
4. Blood Cancer Journal, 2015 -- High expression of PTPN21 in B-cell non-Hodgkin’s gastric lymphoma, a positive mediator of STAT5 activity
5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), 2026 -- Head and Neck Cancers
6. METTL3-mediated m6A methylation of lncRNA PVT1 promotes the progression of oral squamous cell carcinoma via the miR-185-5p/SERPINB4 axis - PMC
7. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
8. METTL3-mediated m6A methylation of lncRNA PVT1 promotes the progression of oral squamous cell carcinoma via the miR-185-5p/SERPINB4 axis - PMC